EGFR突變肺癌的重大突破：泰格莎（Osimertinib）的發展歷程 Major Breakthrough in EGFR-Mutated NSCLC

腫瘤科吳教恩醫師
腫瘤科吳教恩醫師
948粉絲
9 次觀看·2026年2月14日

第三代標靶藥物泰格莎（Osimertinib）在EGFR突變型非小細胞肺癌（NSCLC）的發展歷程十分重要。泰格莎是一種鎖定表皮生長因子受體（EGFR）的標靶藥物，主要應用於治療EGFR基因發生突變的NSCLC。

泰格莎的發展歷史可以追溯到其初次被發現擁有對抗EGFR突變的活性。隨著臨床試驗的進展，泰格莎展現出相對較高的療效，尤其在對抗EGFR T790M 突變的NSCLC病例中表現卓越。

泰格莎的獲准上市標誌著EGFR突變型NSCLC患者在治療方案中的又一選擇。它的開發代表了個體化醫療治療策略的重要進步，使得患者能夠更精準地接受特定基因異常的治療。

The development history of the third-generation targeted therapy, Osimertinib, is critically significant in the context of EGFR-mutated non-small cell lung cancer (NSCLC). Osimertinib is a targeted therapy that specifically inhibits the epidermal growth factor receptor (EGFR), primarily used for treating NSCLC with EGFR gene mutations.

The development of Osimertinib traces back to its initial discovery of having activity against EGFR mutations. With the progression of clinical trials, Osimertinib demonstrated notable efficacy, particularly in cases of NSCLC with the EGFR T790M mutation.

The approval of Osimertinib marked another milestone in the treatment options for patients with EGFR-mutated NSCLC. Its development represents a significant advancement in personalized medical treatment strategies, allowing patients to receive targeted therapy tailored to specific genetic abnormalities.

腫瘤科醫師的生活點滴
臉書facebook：
https://m.facebook.com/profile.php/?id=100063644122566
Instagram：
https://instagram.com/chiaoenpeter?igshid=OGQ5ZDc2ODk2ZA==
加入頻道會員：
https://www.youtube.com/channel/UCBvUlnJq3TpnGtbV6fdnl2A/join
分享會員專屬影片：
https://www.youtube.com/playlist?list=UUMOBvUlnJq3TpnGtbV6fdnl2A